Milan Scheidegger

Dr. Milan Scheidegger

orcid

Research Focus & Metrics

Academic Career Length

57Years (1970-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Biological Psychiatry
Verified
Journal Article
Closed access
RKRainer Kraehenmann
Rainer Kraehenmann
KPKatrin H. Preller
Katrin H. Preller
MSMilan Scheidegger
Milan Scheidegger
TPThomas Pokorny
Thomas Pokorny
OBOliver G. Bosch
Oliver G. Bosch
FVFranz X. Vollenweider
Franz X. Vollenweider

24 September 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMilan Scheidegger
Milan Scheidegger
MWMartin Walter
Martin Walter
MLMick Lehmann
Mick Lehmann
CMCoraline Metzger
Coraline Metzger
SGSimone Grimm
Simone Grimm
ESErich Seifritz
Erich Seifritz
Increasing preclinical and clinical evidence underscores the strong and rapid antidepressant properties of the glutamate-modulating NMDA receptor antagonist ketamine. Targeting the glutamatergic system might thus provide a novel molecular strategy for antidepressant treatment. Since glutamate is the most abundant and major excitatory neurotransmitter in the brain, pathophysiological changes in glutamatergic signaling are likely to affect neurobehavioral plasticity, information processing and large-scale changes in functional brain connectivity underlying certain symptoms of major depressive disorder. Using resting state functional magnetic resonance imaging (rsfMRI), the „dorsal nexus “(DN) was recently identified as a bilateral dorsal medial prefrontal cortex region showing dramatically increased depression-associated functional connectivity with large portions of a cognitive control network (CCN), the default mode network (DMN), and a rostral affective network (AN). Hence, Sheline and colleagues (2010) proposed that reducing increased connectivity of the DN might play a critical role in reducing depression symptomatology and thus represent a potential therapy target for affective disorders. Here, using a randomized, placebo-controlled, double-blind, crossover rsfMRI challenge in healthy subjects we demonstrate that ketamine decreases functional connectivity of the DMN to the DN and to the pregenual anterior cingulate (PACC) and medioprefrontal cortex (MPFC) via its representative hub, the posterior cingulate cortex (PCC). These findings in healthy subjects may serve as a model to elucidate potential biomechanisms that are addressed by successful treatment of major depression. This notion is further supported by the temporal overlap of our observation of subacute functional network modulation after 24 hours with the peak of efficacy following an intravenous ketamine administration in treatment-resistant depression.

18 April 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KPKatrin H. Preller
Katrin H. Preller
TPThomas Pokorny
Thomas Pokorny
AHAndreas Hock
Andreas Hock
RKRainer Kraehenmann
Rainer Kraehenmann
PSPhilipp Stämpfli
Philipp Stämpfli
FVFranz X. Vollenweider
Franz X. Vollenweider
Significance: Social cognition critically impacts the development, progression, and treatment of psychiatric disorders. However, social cognition skills are insufficiently targeted by current treatment approaches. By applying a multimodal brain imaging strategy, the present study demonstrated the importance of the serotonin 2A/1A receptor system in the modulation of social exclusion processing. Understanding the biochemical underpinnings of the social rejection experience is important for increasing our knowledge about social/emotional processing and the related neural responses. The identification of relevant neural responses is in turn crucial for the efficacious management of disorders influenced by social factors. Our findings may help to diminish a knowledge gap that currently restrains the development of pharmacotherapies for sociocognitive deficits in psychiatric disorders.

1 January 2013 in Biological Psychiatry
Verified
Journal Article
Closed access
KHKatharina Hefti
Katharina Hefti
SHSebastian Camillo Holst
Sebastian Camillo Holst
JSJudit Sovago
Judit Sovago
VBValérie Bachmann
Valérie Bachmann
ABAlfred Buck
Alfred Buck
Hans-Peter LandoltHans-Peter Landolt
Hans-Peter Landolt

11 November 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
OBOliver G. Bosch
Oliver G. Bosch
JRJulia S. Rihm
Julia S. Rihm
MSMilan Scheidegger
Milan Scheidegger
Hans-Peter LandoltHans-Peter Landolt
Hans-Peter Landolt
PSPhilipp Stämpfli
Philipp Stämpfli
ESErich Seifritz
Erich Seifritz
Significance: Major depressive disorder is a significant contributor to the global burden of disease, affecting 350 million people according to an estimation of the World Health Organization. Today, no valid biomarkers of depression, which could predict the efficacy of a certain treatment in a certain group of patients, exist. Sleep deprivation is an effective and rapid-acting antidepressive treatment. However, the biomechanism of this effect is largely unknown. This study shows the effects of sleep deprivation on human brain functional connectivity alterations via the dorsal nexus, an area which is crucial in major depressive disorder. Here, we offer a neurobiological explanation for the known antidepressive action of sleep deprivation.

25 February 2016 in Human Brain Mapping
Verified
Journal Article
Closed access
MSMilan Scheidegger
Milan Scheidegger
AHAnke Henning
Anke Henning
MWMartin Walter
Martin Walter
MLMick Lehmann
Mick Lehmann
RKRainer Kraehenmann
Rainer Kraehenmann
SGSimone Grimm
Simone Grimm